Skip to main content
SpringerLink
Log in

Problems and Pitfalls of Sulphonylurea Therapy in Older Patients

  • Review Article
  • Adverse Effects
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The prevalence of non-insulin-dependent diabetes mellitus (type II) increases with age, so that approximately half of all known patients in English-speaking countries are over 65 years of age. There is no reason to believe that the criteria for blood glucose control should be any less stringent for elderly patients unless they have a limited life expectancy. Sulphonylurea drugs remain an effective means of achieving blood glucose control after failure of dietary therapy alone in older patients. However, changes in normal metabolism of drugs with age and the development of other pathologies in elderly patients make it important that these drugs are prescribed with care.

Severe symptomatic hypoglycaemia is the most serious adverse effect of sulphonylurea drugs and this becomes progressively more likely with increasing age, depending primarily on the substantial reduction of renal function with normal aging. Other adverse effects are much less commonly of clinical importance. To minimise the risk of hypoglycaemia, it is important that patients receive closely supervised dietary management with education about their disease for at least 3 months before sulphonylurea drugs are prescribed. In elderly patients a short-acting agent with no active metabolites should be used. As patients become older, those receiving long-acting agents can be changed to short-acting agents before problems arise. If blood glucose control appears satisfactory on treatment, then symptoms of hypoglycaemia should be sought. If control is poor, then the criteria for introduction of insulin, with appropriate education, do not differ from those in younger patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes in Europe: a consensus view. Diabetic Medicine 5: 275–281, 1988

    Article  PubMed  CAS  Google Scholar 

  • Asplund K, Wiholm B-E, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24: 412–417, 1983

    Article  PubMed  CAS  Google Scholar 

  • Asplund K, Wiholm B-E, Lundman B. Severe hypoglycaemia during treatment with glipizide. Diabetic Medicine 8: 726–731, 1991

    Article  PubMed  CAS  Google Scholar 

  • Balant L, Fabré J, Loutan L, Samini H. Does 4-transhydroxy glibenclamide show hypoglycemic activity? Arzneimittel-Forschung 29: 162–163, 1979

    PubMed  CAS  Google Scholar 

  • Behle M. Untersuchung zur pharmakokinetik von glibenclamid bei nierengesunden und nieren insuffizienten diabetikern, Ph.D Thesis, Ruprecht-Karl-Universität, Heidelberg, 1980

    Google Scholar 

  • Bennett PH. Diabetes in the elderly: diagnosis and epidemiology. Geriatrics 39: 37–41, 1984

    PubMed  CAS  Google Scholar 

  • Berger W. 88 schwere Hypoglykämiezwischenfälle unter der Behandlung mit Sulfonylharnstoffen. Schweizerische Medizinische Wochenschrift 71: 1013–1022, 1971

    Google Scholar 

  • Berger W, Caduff F, Pasquel M, Rump A. Die relative Häufigkeit der schwerern Sulfonylharnstoff-Hypoglykämie in der Schweiz. Schweizerische Medizinische Wochenschrift 116: 145–151, 1986

    PubMed  CAS  Google Scholar 

  • Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care 15: 75–80, 1992

    Article  PubMed  CAS  Google Scholar 

  • Campbell IW. Sulphonylureas and metformin: efficacy and inadequacy. In Bailey & Flatt (Eds) New antidiabetic drugs, pp. 33–51, Smith-Gordon, London, 1990

    Google Scholar 

  • Clarke BF. Comparative effectiveness of glyburide in the treatment of non-insulin-dependent diabetes. Postgraduate Medicine 57–65, 1982

    Google Scholar 

  • Clarke BF, Campbell IW. Long term comparative trial of glibenclamide and chlorpropramide in patients with Type II diabetes. Lancet 1: 246–248, 1975

    Article  PubMed  CAS  Google Scholar 

  • Cohen JL. Pharmacokinetic changes in aging. American Journal of Medicine 80 (Suppl. 5A): 31–38, 1986

    Article  PubMed  CAS  Google Scholar 

  • Cohen KL, Harris S. Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemics. Diabetes Care 10: 555–557, 1987

    Article  PubMed  CAS  Google Scholar 

  • Dahlen M, Bergman U, Idman L, Martinsson L, Karlsson G. Epidemiology of hypoglycaemia in patients on oral antidiabetic drugs in the island of Gotland, Sweden. Acta Endocrinologica (Suppl. 263): abstract 21, 1984

    Google Scholar 

  • Davidson M, Lewis AAG, De Mowbray RR, Boucher BJ, Oakley NW, et al. Metabolic and clinical efficacy of glibenclamide. Lancet 1: 57–61, 1970

    Article  PubMed  CAS  Google Scholar 

  • Davidson MB. Rational use of sulphonylureas. Postgraduate Medicine 92: 69–85, 1992

    PubMed  CAS  Google Scholar 

  • Davies DM, Maclntyre A, Millar EJ, Bell SM, Mehra SK. Need for glucagon in severe hypoglycaemia induced by sulphonylurea drugs. Lancet 1: 363–364, 1967

    Article  PubMed  CAS  Google Scholar 

  • Editorial. Oral hypoglycaemics for diabetes: when and which? Drug and Therapeutics Bulletin 29: 13–16, 1991

  • Feinglos MN, Lebovitz HE. Mechanism of action of the second-generation sulfonylurea glipizide. American Journal of Medicine 75: 46–54, 1983a

    Article  PubMed  Google Scholar 

  • Feinglos MN, Lebovitz HE. Long term safety and efficacy of glipizide. American Journal of Medicine 75: 60–66, 1983b

    Article  PubMed  CAS  Google Scholar 

  • Ferguson RP, Wettle T, Dubitzky D, Winsemius D. Relative importance to older patients of effectiveness, side effects, convenience and cost of antihypertensive medications. A pilot study. Drugs & Aging 4: in press, 1994

    Google Scholar 

  • Ferner RE. Oral hypoglycemic agents. Medical Clinics of North America 72: 1323–1335, 1988

    PubMed  CAS  Google Scholar 

  • Ferner RE, Ansiferov ML, Kelman AW, Alberti KGMM, Rawlins MD. The relationship between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes. European Journal of Clinical Pharmacology 40: 163–168, 1991

    Article  PubMed  CAS  Google Scholar 

  • Ferner RE, Chaplin S. The relationship between the pharmacokinetic and pharmacodynamic effects of oral hypoglycaemic drugs. Clinical Pharmacokinetics 12: 379–401, 1987

    Article  PubMed  CAS  Google Scholar 

  • Ferner RE, Neil HAW. Sulphonylureas and hypoglycaemia. British Medical Journal 296: 949–950, 1988

    Article  PubMed  CAS  Google Scholar 

  • Ferner RE, Rawlins MD, Alberti KGMM. Impaired B-cell responses improve when fasting blood glucose concentration is reduced in noninsulin dependent diabetes. Quarterly Journal of Medicine 250: 137–146, 1988

    Google Scholar 

  • Fleig WE, Noether-Fleig G, Fussgaenger R, Ditschuneit H. Modulation by a sulfonylurea of insulin-dependent glycogenesis, but not of insulin binding in cultured rat hepatocytes. Evidence for a postreceptor mechanism of action. Diabetes 33: 285–290, 1984

    Article  PubMed  CAS  Google Scholar 

  • Gerich J. Oral hypoglycemic agents. New England Journal of Medicine 321: 1231–1245, 1989

    Article  PubMed  CAS  Google Scholar 

  • Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. New England Journal of Medicine 306: 1081–1088, 1982

    Article  PubMed  CAS  Google Scholar 

  • Greenfield MS, Doberne L, Rosenthal M, Schultz B, Widström A, et al. Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin dependent diabetes mellitus. Diabetes 31: 307–312, 1981

    Article  Google Scholar 

  • Groop LC. Sulfonylureas in NIDDM. Diabetes Care 15: 737–754, 1992

    Article  PubMed  CAS  Google Scholar 

  • Groop LC, Luzi L, DeFronzo RA, Melander A. Hyperglycaemia and absorption of sulphonylurea drugs. Lancet 2: 129–130, 1989

    Article  PubMed  CAS  Google Scholar 

  • Groop LC, Luzi L, Mellander A, Groop P-H, Ratheiser K, et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 36: 1320–1328, 1987

    Article  PubMed  CAS  Google Scholar 

  • Groop LC, Ratheiser K, Luzi L, Melander A, Simonson DC, et al. Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study. Acta Diabetologica 28: 162–168, 1991

    Article  PubMed  CAS  Google Scholar 

  • Harris MI. Epidemiology of diabetes mellitus among the elderly in the United States. Clinics in Geriatric Medicine 6: 703–719, 1990

    PubMed  CAS  Google Scholar 

  • Hirokawa CA, Gray DR. Chlorpropramide-induced hyponatremia in the veteran population. Annals of Pharmacotherapy 26: 1243–1244, 1992

    PubMed  CAS  Google Scholar 

  • Hoskins PJ, Wiles PG, Volkmann HP, Pyke DA. Chlorpropramide alcohol flushing: a normal response? Clinical Science 73: 77–80, 1987

    PubMed  CAS  Google Scholar 

  • Jackson EJ, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents. Drugs 22: 211–245, 1981a

    Article  PubMed  CAS  Google Scholar 

  • Jackson EJ, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents. Drugs 22: 295–320, 1981b

    Article  PubMed  CAS  Google Scholar 

  • Janbon M, Chaptal J, Vedel A, Schaap J. Accidents hypoglycémique graves par un sulfamidiothiodiazol. Montpellier Medicale 21/22: 441–444, 1942

    Google Scholar 

  • Johnson SF, Schade DS, Peake GT. Chlorpropramide-induced hypoglycemia: successful treatment with diazoxide. American Journal of Medicine 63: 799–804, 1977

    Article  PubMed  CAS  Google Scholar 

  • Judzewitsch RG, Pfeifer MA, Best JD, Beard JC, Halter JB, et al. Chronic chlorpropramide therapy of non-insulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. Journal of Clinical Endocrinology and Metabolism 55: 321–328, 1982

    Article  PubMed  CAS  Google Scholar 

  • Katz HM, Bisseil G. Blood sugar lowering effects of chlorpropramide and tolbutamide. A double-blind co-operative study. Diabetes 14: 650–657, 1965

    PubMed  CAS  Google Scholar 

  • Kobayashi KA, Bauer LA, Horn JR, Opheim K, Wood F Jr, et al. Glipizide pharmacokinetics in young and elderly volunteers. Clinical Pharmacokinetics 7: 224–228, 1988

    CAS  Google Scholar 

  • Kradjan WA, Kobayashi KA, Bauer LA, Opheim KE, Wood F Jr. Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing. Journal of Clinical Pharmacology 29: 1121–1127, 1989

    PubMed  CAS  Google Scholar 

  • Krall LP, Chabot VA. Oral hypoglycemic agent update. Medical Clinics of North America 62: 681–694, 1978

    PubMed  CAS  Google Scholar 

  • Kreisberg RA. The second-generation sulfonylureas: change or progress? Annals of Internal Medicine 102: 125–126, 1985

    PubMed  CAS  Google Scholar 

  • Krentz AJ, Boyle PJ, Justice KM, Wright AD, Schade DS. Octreotide: a new treatment for severe sulphonylurea-induced hypoglycaemia. Abstract. Diabetic Medicine 9: P151, 1992

    Article  Google Scholar 

  • Lipson LG. Diabetes in the elderly: diagnosis, pathogenesis and treatment. American Journal of Medicine 80 (Suppl. 5A): 10–21, 1986

    Article  PubMed  CAS  Google Scholar 

  • Loubatières A. History and development of the oral hypoglycaemic agents. In Campbell (Ed.) Oral hypoglycaemic agents, Academic Press, London, 1969

    Google Scholar 

  • Lundgren H, Björkman L, Keiding P, Lundmark S, Bengtsson C. Diabetes in patients with hypertension receiving pharmacological treatment. British Medical Journal 297: 1512, 1988

    Article  PubMed  CAS  Google Scholar 

  • MacLennan WJ, Peden NR. Metabolic and endocrine problems in the elderly, Springer Verlag, London, 1989

    Book  Google Scholar 

  • Malaisse WJ, Lebrun P. Mechanism of sulfonylurea-induced insulin release. Diabetes Care 13 (Suppl. 3): 9–17, 1990

    PubMed  Google Scholar 

  • Maloff BL, Lockwood DH. In vitro effects of a sulfonylurea on insulin action in adipocytes: potentiation of insulin-stimulated hexose transport. Journal of Clinical Investigation 68: 85–90, 1981

    Article  PubMed  CAS  Google Scholar 

  • Marshall SM, Alberti KGMM. Hyperosmolar non-ketotic diabetic coma. In Alberti & Krall (Eds) The diabetes annual/4, pp. 235–247, Elsevier Science Publishers, Amsterdam, 1988

    Google Scholar 

  • Martin BJ, Kesson CM. Dietary control of elderly diabetic patients. Practical Diabetes 3: 146–148, 1986

    Article  Google Scholar 

  • McIntyre HD, Ma A, Bird DM, Patterson CA, Cameron DP. Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se. Diabetes Care 15: 1534–1540, 1992

    Article  PubMed  CAS  Google Scholar 

  • Melander A. Sulphonylureas in the treatment of non-insulin-dependent diabetes. Bailliere’s Clinical Endocrinology and Metabolism 2: 443–453, 1988

    Article  PubMed  CAS  Google Scholar 

  • Melander A, Lebovitz HE, Faber OK. Sulfonylureas. Why, which and how? Diabetes Care 13 (Suppl. 3): 18–25, 1990

    PubMed  Google Scholar 

  • Melander A, Sartor G, Wåhlin-Boll E, Scherstén B, Bitzén P-O. Serum tolbutamide and chlorpropramide concentrations in patients with diabetes mellitus. British Medical Journal 1: 142–144, 1978

    Article  PubMed  CAS  Google Scholar 

  • Menelly GS, Bryer-Ash M, Elahi D. The effect of glyburide on β-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care 16: 110–114, 1993

    Article  Google Scholar 

  • Miller JL, Salman K, Shulman LH, Rose LI. Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes. Clinical Pharmacology and Therapeutics 53: 380–384, 1993

    Article  PubMed  CAS  Google Scholar 

  • Morley JE, Perry HM 3rd. The management of diabetes mellitus in older individuals. Drugs 41: 548–565, 1991

    Article  PubMed  CAS  Google Scholar 

  • Moses AM, Miller M. Diuretic action of three sulphonylurea drugs. Annals of Internal Medicine 78: 541–544, 1973

    PubMed  CAS  Google Scholar 

  • Mutch WJ, Dingwall-Fordyce I. Is it a hypo? Knowledge of the symptoms of hypoglycaemia in elderly diabetic patients. Diabetic Medicine 2: 54–58, 1985

    Article  PubMed  CAS  Google Scholar 

  • Nattrass M. Treatment of type II diabetes. British Medical Journal 292: 1033–1034, 1986

    Article  PubMed  CAS  Google Scholar 

  • Niskanen L, Lahti J, Uusitupa M. Morning or bed-time insulin with or without glibenclamide in elderly type 2 diabetic patients unresponsive to oral antidiabetic agents. Diabetes Research and Clinical Practice 18: 185–190, 1992

    Article  PubMed  CAS  Google Scholar 

  • Nolan L, O’Malley K. Prescribing for the elderly. Part II. Prescribing patterns: differences due to age. Journal of the American Geriatrics Society 36: 245–254, 1984

    Google Scholar 

  • Noyes MA, Carter BL, Helling DK, McCormick WC, Ramirez R. Evaluation of glipizide and glyburide in a health maintenance organisation. Annals of Pharmacotherapy 26: 1215–1220, 1992

    PubMed  CAS  Google Scholar 

  • Paice BJ, Paterson KR, Lawson DH. Undesired effects of sulfonylurea drugs. Adverse Drug Reactions and Acute Poisons Review 1: 23–36, 1985

    Google Scholar 

  • Palmer KJ, Brogden RG. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 46: 92–125, 1993

    Article  PubMed  CAS  Google Scholar 

  • Paterson AJ, Lamey PJ, Lewis MAO, Nolan A, Rademaker M. Pemphigus vulgaris precipitated by glibenclamide therapy. Journal of Oral Pathology and Medicine 22: 92–95, 1993

    Article  PubMed  CAS  Google Scholar 

  • Peters AL, Davidson MB. Use of sulfonylurea agents in older diabetic patients. Clinics in Geriatric Medicine 6: 903–921, 1990

    PubMed  CAS  Google Scholar 

  • Petri MP, Gatling W, Petri LM, Hill RD. Diabetes in the elderly, an epidemiological perspective. Practical Diabetes 3: 152–155, 1986

    Article  Google Scholar 

  • Phillips PA, Rolls BJ, Ledingham JGG, Forsling ML, Morton JJ, et al. Reduced thirst after H2O deprivation in healthy elderly men. New England Journal of Medicine 311: 753–759, 1984

    Article  PubMed  CAS  Google Scholar 

  • Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, et al. Infection and diabetes: the case for control. American Journal of Medicine 72: 439–450, 1982

    Article  PubMed  CAS  Google Scholar 

  • Rowe JW. Health care of the elderly. New England Journal of Medicine 312: 827–835, 1985

    Article  PubMed  CAS  Google Scholar 

  • Ruoff G. The management of non-insulin-dependent diabetes mellitus in the elderly. Journal of Family Practice 36: 329–335, 1993

    PubMed  CAS  Google Scholar 

  • Salhanick AI, Konowitz P, Amatruda JM. Potentiation of insulin action by a sulfonylurea in primary cultures of hepatic cells from normal and diabetic rats. Diabetes 32: 206–212, 1983

    Article  PubMed  CAS  Google Scholar 

  • Sartor G, Melander A, Scherstén B, Wåhlin-Boll E. Influence of food and age on the single-dose kinetics and effects of tolbutamide and chlorpropramide. European Journal of Clinical Pharmacology 17: 285–293, 1980

    Article  PubMed  CAS  Google Scholar 

  • Schmucker DL. Aging and drug disposition: an update. Pharmacology Reviews 37: 133–148, 1985

    CAS  Google Scholar 

  • Schwinghammer TL, Antal AJ, Kubacka RT, Hackimer ME, Johnston JM. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly nondiabetic adults. Clinical Pharmacology 10: 532–538, 1991

    CAS  Google Scholar 

  • Seltzer HS. Drug-induced hypoglycaemia: a review based on 473 cases. Diabetes 21: 955–966, 1972

    PubMed  CAS  Google Scholar 

  • Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinology and Metabolism Clinics in North America 18: 163–183, 1989

    CAS  Google Scholar 

  • Simonson DC, Ferrannini E, Bevilacqua S, Smith D, Barrett E, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 33: 838–845, 1983

    Article  Google Scholar 

  • Soneru IL, Agrawal L, Murphy JC, Lawrence AM, Abraira C. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure. Diabetes Care 16: 896–901, 1993

    Article  PubMed  CAS  Google Scholar 

  • Stenman S, Melander A, Groop P-H, Groop L. What is the benefit of increasing the sulfonylurea dose? Annals of Internal Medicine 118: 169–172, 1993

    PubMed  CAS  Google Scholar 

  • Stewart RB, Caranasos GJ. Medication compliance in the elderly. Medical Clinics of North America 73: 1551–1563, 1989

    PubMed  CAS  Google Scholar 

  • Tattersall RB, Scott AR. When to use insulin in the maturity onset diabetic. Postgraduate Medical Journal 63: 859–864, 1987

    Article  PubMed  CAS  Google Scholar 

  • Taylor R. Insulin for the non-insulin dependent? British Medical Journal 296: 1015–1016, 1989

    Article  Google Scholar 

  • Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance. Implications for the management of diabetes. Diabetologia 28: 119–121, 1985

    Article  PubMed  CAS  Google Scholar 

  • University Group Diabetes Program. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. II Mortality results. Diabetes 19 (Suppl. 2): 785–830, 1970

    Google Scholar 

  • Vinik A, Jackson WPU, Keller P, Marine N. Metabolic studies in diabetics on tolbutamide. Comparison of a single dose with a divided dose regime. Diabetologia 4: 203–209, 1968

    Article  PubMed  CAS  Google Scholar 

  • Wåhlin-Boll E, Groop L, Karhumaa S, Groop PH, Tötterman KJ, et al. Therapeutic equivalence of once- and thrice-daily glipizide. European Journal of Clinical Pharmacology 31: 95–99, 1986

    Article  PubMed  Google Scholar 

  • Wåhlin-Boll E, Sartor G, Melander A, Scherstén B. Impaired effect of sulphonylurea following increased dosage. European Journal of Clinical Pharmacology 22: 21–25, 1982

    Article  PubMed  Google Scholar 

  • Ward EA, Lang DA, Philipps MR, Turner RC. Comparison of chlorpropramide and glibenclamide treatment of maturity-onset diabetes: control assessed by fasting glucose concentrations. Diabetes Care 4: 293–295, 1981

    Article  PubMed  CAS  Google Scholar 

  • Ward G, Harrison LC, Proietto J, Aitken P, Nankervis A. Gliclazide therapy is associated with potentiation of post-binding insulin action in obese, non-insulin-dependent diabetic subjects. Diabetes 34: 241–245, 1985

    Article  PubMed  CAS  Google Scholar 

  • Ziegler O, Drouin P. Hemobiological activity of gliclazide in diabetes mellitus. Diabetes Research and Clinical Practice 14: S83–S90, 1991

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Framlington Place, Newcastle upon Tyne, England

    D. A. Robertson &  P. D. Home

Authors
  1. D. A. Robertson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. D. Home
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robertson, D.A., Home, P.D. Problems and Pitfalls of Sulphonylurea Therapy in Older Patients. Drugs & Aging 3, 510–524 (1993). https://doi.org/10.2165/00002512-199303060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199303060-00005

Keywords

Search

Navigation